Youmanitarian 11 Jun 2021

تشغيل تلقائي

Kerrville, Texas flooding update: Several confirmed dead as evacuations, rescue efforts continue alo

Youmanitarian · 24 المشاهدات

KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer

7 المشاهدات

TAKE ACTION

Donations would go to support charities for كيف تصمم

في كيف تصمم

Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the KEYNOTE-100 trial (NCT02674061) of pembrolizumab in advanced recurrent ovarian cancer patients. Importantly, no significant difference in response rate was found between heavily and less heavily pretreated patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

أظهر المزيد

More ways to take action

Explore ways that you can help bring a solution to this issue.

Create Youms with
hashtags كيف تصمم

Create a challenge to
bring awareness to this issue for people to complete

Create a fundraiser to
support a charity that tackle this issue

Volunteer at charitable organization
that support this cause

Create a movement page dedicated to this cause to bring awareness.

Start a uCharity for this cause and invite people to join it to support this cause

تشغيل تلقائي

Kerrville, Texas flooding update: Several confirmed dead as evacuations, rescue efforts continue alo

Youmanitarian · 24 المشاهدات

التالي

KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer

التالي

الاقسام

يرجى ملاحظة أنه إذا كان عمرك أقل من 18 عامًا ، فلن تتمكن من الوصول إلى هذا الموقع.

التالي

KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer

التالي

الاقسام

اختيار طريقة الدفع